arrow_back Back to App

Urging FDA to Reevaluate Safety of Chemical Abortion Drugs

The House of Representatives is urging the Food and Drug Administration (FDA) to reevaluate the safety of all chemical abortion drugs. This call comes in light of new independent studies suggesting a significantly higher rate of serious complications than previously reported. Citizens can expect a public release of a full safety review, which could impact the availability and use of these drugs.
Key points
Request for the FDA to reevaluate the safety of chemical abortion drugs based on recent independent studies.
Demand for a public release of a comprehensive safety review of these drugs, including real-world outcomes and complications.
Highlighting concerns about increased risks of complications, coercion, and misuse associated with expanded access to these drugs.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HRES_803
Sponsor: Rep. Rose, John W. [R-TN-6]
Process start date: 2025-10-10
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HRES_803.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-10-10.

What are the main provisions?

Key points include:

  • Request for the FDA to reevaluate the safety of chemical abortion drugs based on recent independent studies.
  • Demand for a public release of a comprehensive safety review of these drugs, including real-world outcomes and complications.
  • Highlighting concerns about increased risks of complications, coercion, and misuse associated with expanded access to these drugs.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Rose, John W. [R-TN-6].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

CATEGORIES

Health